Opko Health Inc (OPK) 9.75 $OPK
Opko Health (OPK) Catches Eye: Stock Adds 5.6% in Session
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 7:15AM CDT
Opko Health, Inc. (OPK) shares rose almost 6% in the last trading session.
OPK: 9.75 (+0.39), CRY: 11.94 (+0.09)
Here's Why Opko Health (OPK) Stock Is Gaining Today
Ryan McQueeney - Zacks Investment Research - Tue Jun 21, 11:31AM CDT
Shares of Opko Health (OPK) are up nearly 5.5% in morning trading Tuesday following the news that the FDA has approved its new treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease.
OPK: 9.75 (+0.39)
Company News for June 21, 2016
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 9:10AM CDT
Companies in the News are: MRO,OPK,DIS,LC
LC: 4.98 (+0.14), OPK: 9.75 (+0.39), DIS: 99.02 (+0.23), MRO: 15.27 (+0.52)
VBI Vaccines Announces Closing of $13.6 Million Private Placement
Marketwire Canada - Tue Jun 21, 7:30AM CDT
CAMBRIDGE, MASSACHUSETTS--(Marketwired - Jun 21, 2016) - VBI Vaccines (NASDAQ:VBIV)(TSX:VBV) ("VBI"
, today announced the closing of an equity private placement financing led by OPKO Health (NYSE:OPK) and Perceptive Advisors, with participation by ARCH Venture Partners. In accordance with Toronto Stock Exchange (TSX) regulations, aggregate participation by certain current investors was limited to 10% of the issued and outstanding common shares in any given 6-month period. As a result, these current investors in VBI participated to their maximum possible allocation.
OPK: 9.75 (+0.39), VBIV: 3.93 (+0.06), VBV.TO: 5.00 (+0.10)
FDA Approves New Drug Application for RAYALDEE(R) to Treat Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Stage 3-4 Chronic Kidney Disease
BusinessWire - Tue Jun 21, 1:00AM CDT
--There are Approximately 9 Million Patients in the U.S. with SHPT, Stage 3 or 4 CKD and Vitamin D Insufficiency; Large Potential U.S. Market
OPK: 9.75 (+0.39)
Opko Health Inc Enters Oversold Territory (OPK)
MarketNewsVideo.com - Tue Jun 14, 11:09AM CDT
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative...
OPK: 9.75 (+0.39)
OPKO Health Announces Move to NASDAQ Stock Market
BusinessWire - Mon Jun 13, 8:10AM CDT
OPKO Health, Inc. (NYSE:OPK) ("OPKO" or the "Company" announces that it will move its stock exchange listing to The NASDAQ Stock Market from The New York Stock Exchange (the "NYSE". The Company expects its common stock will begin trading on the NASDAQ Global Select Market ("NASDAQ" on June 24, 2016, and its shares will continue to trade under the ticker symbol "OPK."
OPK: 9.75 (+0.39)
Covered Call Alerts For Gilead Sciences, Western Digital, Costco, Opko Health and Ulta Salon Cosmetics & Fragrance Inc. Released By InvestorsObserver
PR Newswire - Wed Jun 08, 9:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GILD, WDC, COST, OPK and ULTA.
OPK: 9.75 (+0.39), GILD: 83.37 (+0.92), COST: 157.03 (-1.09), ULTA: 242.08 (+3.85), WDC: 50.81 (+2.46)
OPKO to Discuss Draft Coverage Determinations for 4Kscore(R) Test at 2016 Jefferies Healthcare Conference
BusinessWire - Tue Jun 07, 3:05PM CDT
OPKO Health, Inc. (NYSE: OPK) today announced that senior management will discuss recent draft local coverage determinations by certain Medicare Administrative Contractors for OPKO's 4Kscore(R) test at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2016 at 11:30 AM (EDT). OPKO previously announced that Novitas Solutions issued a positive draft local coverage determination proposing to establish reimbursement coverage for patients with PSA levels > 3 ng/mL who have not yet had a biopsy, or patients with a PSA level of > 3 ng/mL who have had at least one prior negative biopsy and are considered to be at higher risk. The draft coverage determination was subsequently retired by Novitas due to a potential conflict with another Medicare Administrative Contractor. Palmetto GBA had issued a draft non-coverage determination on May 27th for the 4Kscore test.
OPK: 9.75 (+0.39)
Biotechnology Stocks in Motion -- Celldex Therapeutics, Medivation, Opko Health, and ACADIA Pharma
PR Newswire - Tue Jun 07, 7:05AM CDT
On Monday, June 06, 2016, the NASDAQ Composite ended the trading session at 4,968.71, up 0.53%; the Dow Jones Industrial Average advanced 0.64% to finish at 17,920.33; and the S&P 500 closed at 2,109.41, up 0.49%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Celldex Therapeutics Inc. (NASDAQ: CLDX), Medivation Inc. (NASDAQ: MDVN), Opko Health Inc. (NYSE: OPK), and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). Learn more about these stocks by accessing their free trade alerts at:
MDVN: 59.26 (+0.37), ACAD: 33.50 (unch), OPK: 9.75 (+0.39), CLDX: 4.57 (+0.12)
OPKO Health to Present at the 2016 Jefferies Healthcare Conference
BusinessWire - Thu Jun 02, 7:47AM CDT
OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2016 at 11:30 AM (EDT).
OPK: 9.75 (+0.39)
OPKO Health Receives Proposed/Draft Medicare Local Coverage Determination for 4Kscore(R) Test
BusinessWire - Fri May 27, 7:30AM CDT
OPKO Health, Inc. (NYSE:OPK) ("OPKO" or the "Company" announces that Novitas Solutions has issued a draft local coverage determination for the 4Kscore(R) Test, the only blood test that accurately identifies an individual patient's risk for high-grade, aggressive prostate cancer. Novitas Solutions is a Medicare Administrative Contractor (MAC) for Medicare jurisdictions L and H, with responsibility for nearly 10 million Medicare beneficiaries in New Jersey, Pennsylvania, Maryland, the District of Columbia and Texas, among other geographies.
OPK: 9.75 (+0.39)
Global Vitamin D Deficiency Disorders Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Merck, OPKO Health, DSM Biologics Holdings - Research and Markets
BusinessWire - Fri May 27, 6:57AM CDT
Research and Markets has announced the addition of the "Vitamin D Deficiency Disorders Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
OPK: 9.75 (+0.39), MRK: 57.68 (+0.64)
OPKO Health, Inc. - Product Pipeline Review - 2016 - Research and Markets
BusinessWire - Thu May 26, 4:36PM CDT
Research and Markets has announced the addition of the "OPKO Health, Inc. - Product Pipeline Review - 2016" company profile to their offering.
OPK: 9.75 (+0.39)
Under Armour trade offers a 19% return in 52 days, or find similar option trades on Opko Health, Herbalife, Costco, and Microsoft
PR Newswire - Wed May 25, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for UA, OPK, HLF, COST and MSFT.
UA: 38.32 (+0.63), HLF: 62.33 (+3.16), OPK: 9.75 (+0.39), COST: 157.03 (-1.09), MSFT: 51.91 (+0.92)
Cocrystal Pharma to Present at Jefferies 2016 Healthcare Conference
Marketwired - Wed May 25, 7:01AM CDT
Cocrystal CEO & CMO to Present Thursday, June 9, 2016, 8:30 AM ET in NYC
OPK: 9.75 (+0.39)
Learn how to target a 20% return on Google Inc, or get option-trade ideas on LinkedIn, Opko Health, Seagate Technology, and First Solar or any stock you choose
PR Newswire - Mon May 16, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GOOG, LNKD, OPK, STX and FSLR.
FSLR: 48.65 (+0.03), LNKD: 190.45 (+0.13), OPK: 9.75 (+0.39), STX: 24.48 (+0.61), GOOG: 701.87 (+4.41)
OPKO Announces Appointment of Douglass Laidlaw as Vice President of Medical Affairs
BusinessWire - Wed May 11, 7:30AM CDT
OPKO Health, Inc. (NYSE:OPK) today announced the appointment of Douglass Laidlaw, PhD as Vice President of Medical Affairs to support the anticipated launch of RAYALDEE(R).
OPK: 9.75 (+0.39)
Opko Health (OPK) Catches Eye: Stock Adds 5.6% in Session
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 7:15AM CDT
Opko Health, Inc. (OPK) shares rose almost 6% in the last trading session.
OPK: 9.75 (+0.39), CRY: 11.94 (+0.09)
Here's Why Opko Health (OPK) Stock Is Gaining Today
Ryan McQueeney - Zacks Investment Research - Tue Jun 21, 11:31AM CDT
Shares of Opko Health (OPK) are up nearly 5.5% in morning trading Tuesday following the news that the FDA has approved its new treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease.
OPK: 9.75 (+0.39)
Company News for June 21, 2016
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 9:10AM CDT
Companies in the News are: MRO,OPK,DIS,LC
LC: 4.98 (+0.14), OPK: 9.75 (+0.39), DIS: 99.02 (+0.23), MRO: 15.27 (+0.52)
VBI Vaccines Announces Closing of $13.6 Million Private Placement
Marketwire Canada - Tue Jun 21, 7:30AM CDT
CAMBRIDGE, MASSACHUSETTS--(Marketwired - Jun 21, 2016) - VBI Vaccines (NASDAQ:VBIV)(TSX:VBV) ("VBI"
, today announced the closing of an equity private placement financing led by OPKO Health (NYSE:OPK) and Perceptive Advisors, with participation by ARCH Venture Partners. In accordance with Toronto Stock Exchange (TSX) regulations, aggregate participation by certain current investors was limited to 10% of the issued and outstanding common shares in any given 6-month period. As a result, these current investors in VBI participated to their maximum possible allocation. OPK: 9.75 (+0.39), VBIV: 3.93 (+0.06), VBV.TO: 5.00 (+0.10)
FDA Approves New Drug Application for RAYALDEE(R) to Treat Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Stage 3-4 Chronic Kidney Disease
BusinessWire - Tue Jun 21, 1:00AM CDT
--There are Approximately 9 Million Patients in the U.S. with SHPT, Stage 3 or 4 CKD and Vitamin D Insufficiency; Large Potential U.S. Market
OPK: 9.75 (+0.39)
Opko Health Inc Enters Oversold Territory (OPK)
MarketNewsVideo.com - Tue Jun 14, 11:09AM CDT
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative...
OPK: 9.75 (+0.39)
OPKO Health Announces Move to NASDAQ Stock Market
BusinessWire - Mon Jun 13, 8:10AM CDT
OPKO Health, Inc. (NYSE:OPK) ("OPKO" or the "Company"
announces that it will move its stock exchange listing to The NASDAQ Stock Market from The New York Stock Exchange (the "NYSE". The Company expects its common stock will begin trading on the NASDAQ Global Select Market ("NASDAQ" on June 24, 2016, and its shares will continue to trade under the ticker symbol "OPK." OPK: 9.75 (+0.39)
Covered Call Alerts For Gilead Sciences, Western Digital, Costco, Opko Health and Ulta Salon Cosmetics & Fragrance Inc. Released By InvestorsObserver
PR Newswire - Wed Jun 08, 9:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GILD, WDC, COST, OPK and ULTA.
OPK: 9.75 (+0.39), GILD: 83.37 (+0.92), COST: 157.03 (-1.09), ULTA: 242.08 (+3.85), WDC: 50.81 (+2.46)
OPKO to Discuss Draft Coverage Determinations for 4Kscore(R) Test at 2016 Jefferies Healthcare Conference
BusinessWire - Tue Jun 07, 3:05PM CDT
OPKO Health, Inc. (NYSE: OPK) today announced that senior management will discuss recent draft local coverage determinations by certain Medicare Administrative Contractors for OPKO's 4Kscore(R) test at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2016 at 11:30 AM (EDT). OPKO previously announced that Novitas Solutions issued a positive draft local coverage determination proposing to establish reimbursement coverage for patients with PSA levels > 3 ng/mL who have not yet had a biopsy, or patients with a PSA level of > 3 ng/mL who have had at least one prior negative biopsy and are considered to be at higher risk. The draft coverage determination was subsequently retired by Novitas due to a potential conflict with another Medicare Administrative Contractor. Palmetto GBA had issued a draft non-coverage determination on May 27th for the 4Kscore test.
OPK: 9.75 (+0.39)
Biotechnology Stocks in Motion -- Celldex Therapeutics, Medivation, Opko Health, and ACADIA Pharma
PR Newswire - Tue Jun 07, 7:05AM CDT
On Monday, June 06, 2016, the NASDAQ Composite ended the trading session at 4,968.71, up 0.53%; the Dow Jones Industrial Average advanced 0.64% to finish at 17,920.33; and the S&P 500 closed at 2,109.41, up 0.49%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Celldex Therapeutics Inc. (NASDAQ: CLDX), Medivation Inc. (NASDAQ: MDVN), Opko Health Inc. (NYSE: OPK), and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). Learn more about these stocks by accessing their free trade alerts at:
MDVN: 59.26 (+0.37), ACAD: 33.50 (unch), OPK: 9.75 (+0.39), CLDX: 4.57 (+0.12)
OPKO Health to Present at the 2016 Jefferies Healthcare Conference
BusinessWire - Thu Jun 02, 7:47AM CDT
OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2016 at 11:30 AM (EDT).
OPK: 9.75 (+0.39)
OPKO Health Receives Proposed/Draft Medicare Local Coverage Determination for 4Kscore(R) Test
BusinessWire - Fri May 27, 7:30AM CDT
OPKO Health, Inc. (NYSE:OPK) ("OPKO" or the "Company"
announces that Novitas Solutions has issued a draft local coverage determination for the 4Kscore(R) Test, the only blood test that accurately identifies an individual patient's risk for high-grade, aggressive prostate cancer. Novitas Solutions is a Medicare Administrative Contractor (MAC) for Medicare jurisdictions L and H, with responsibility for nearly 10 million Medicare beneficiaries in New Jersey, Pennsylvania, Maryland, the District of Columbia and Texas, among other geographies. OPK: 9.75 (+0.39)
Global Vitamin D Deficiency Disorders Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Merck, OPKO Health, DSM Biologics Holdings - Research and Markets
BusinessWire - Fri May 27, 6:57AM CDT
Research and Markets has announced the addition of the "Vitamin D Deficiency Disorders Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
OPK: 9.75 (+0.39), MRK: 57.68 (+0.64)
OPKO Health, Inc. - Product Pipeline Review - 2016 - Research and Markets
BusinessWire - Thu May 26, 4:36PM CDT
Research and Markets has announced the addition of the "OPKO Health, Inc. - Product Pipeline Review - 2016" company profile to their offering.
OPK: 9.75 (+0.39)
Under Armour trade offers a 19% return in 52 days, or find similar option trades on Opko Health, Herbalife, Costco, and Microsoft
PR Newswire - Wed May 25, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for UA, OPK, HLF, COST and MSFT.
UA: 38.32 (+0.63), HLF: 62.33 (+3.16), OPK: 9.75 (+0.39), COST: 157.03 (-1.09), MSFT: 51.91 (+0.92)
Cocrystal Pharma to Present at Jefferies 2016 Healthcare Conference
Marketwired - Wed May 25, 7:01AM CDT
Cocrystal CEO & CMO to Present Thursday, June 9, 2016, 8:30 AM ET in NYC
OPK: 9.75 (+0.39)
Learn how to target a 20% return on Google Inc, or get option-trade ideas on LinkedIn, Opko Health, Seagate Technology, and First Solar or any stock you choose
PR Newswire - Mon May 16, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GOOG, LNKD, OPK, STX and FSLR.
FSLR: 48.65 (+0.03), LNKD: 190.45 (+0.13), OPK: 9.75 (+0.39), STX: 24.48 (+0.61), GOOG: 701.87 (+4.41)
OPKO Announces Appointment of Douglass Laidlaw as Vice President of Medical Affairs
BusinessWire - Wed May 11, 7:30AM CDT
OPKO Health, Inc. (NYSE:OPK) today announced the appointment of Douglass Laidlaw, PhD as Vice President of Medical Affairs to support the anticipated launch of RAYALDEE(R).
OPK: 9.75 (+0.39)
